Small,
Journal Year:
2025,
Volume and Issue:
unknown
Published: May 7, 2025
Abstract
Biological
environment‐adaptable
polymer
nanocapsules
capable
of
overcoming
multiple
biological
barriers
and
efficiently
realizing
on‐demand
drug
delivery
to
the
target
tumor
cells
are
highly
promising
for
cancer
therapy,
but
their
development
remains
challenging.
Herein,
efficient
synthesis
well‐defined
multi‐responsive
hydrophilic
hairy
fluorescent
molecularly
imprinted
(MIP)
is
reported
address
this
issue,
which
have
a
disulfide‐crosslinked
MIP
shell
with
sialic
acid
(SA,
generally
overexpressed
on
cells)‐imprinted
binding
sites,
some
poly(methacrylic
acid)
chains
inside
cavities,
surface‐grafted
(via
dynamic
benzoic‐imine
bond)
block
copolymer
brushes
thermo/pH‐responsive
(collapse/stretching)
inner
outer
block.
They
show
excellent
aqueous
dispersity,
good
bio/hemocompatibility,
tumor‐microenvironment‐triggered
detachment
(allowing
exposure
SA‐imprinted
sites
negative‐to‐positive
surface
charge
reversal)
(glutathione‐induced)
degradation.
Particularly,
they
also
exhibit
integrated
properties
an
ultrahigh
antitumor
(5‐fluorouracil)
loading
capacity
(688
µmol
g
−1
),
negligible
premature
release,
largely
prolonged
blood
circulation,
specific
sustainable
site
accumulation,
enhanced
penetration,
rapid
release
cells,
enable
them
significantly
inhibit
growth
mice.
This
study
opens
new
access
well‐tailored
smart
“all‐in‐one”‐type
carriers
as
versatile
nanoplatform
various
therapies
by
simply
different
or
drugs.
MedComm,
Journal Year:
2025,
Volume and Issue:
6(3)
Published: Feb. 23, 2025
Ferroptosis
is
a
distinct
form
of
iron-dependent
programmed
cell
death
characterized
primarily
by
intracellular
iron
accumulation
and
lipid
peroxidation.
Multiple
cellular
processes,
including
amino
acid
metabolism,
various
signaling
pathways,
autophagy,
have
been
demonstrated
to
influence
the
induction
progression
ferroptosis.
Recent
investigations
elucidated
that
ferroptosis
plays
crucial
role
in
pathogenesis
pulmonary
disorders,
lung
injury,
chronic
obstructive
disease,
fibrosis,
asthma.
increasingly
recognized
as
promising
novel
strategy
for
cancer
treatment.
Various
immune
cells
within
tumor
microenvironment,
CD8+
T
cells,
macrophages,
regulatory
natural
killer
dendritic
shown
induce
modulate
process
through
regulation
metabolism
pathways.
Conversely,
can
reciprocally
alter
metabolic
environment,
leading
activation
or
inhibition
functions,
thereby
modulating
responses.
This
paper
reviews
molecular
mechanism
describes
discusses
connection
between
microenvironment
diseases,
development
prospect
their
interaction
treatment
diseases.
Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
17(2), P. 245 - 245
Published: Feb. 13, 2025
Recent
advancements
in
nanotechnology
have
revolutionized
cancer
therapy-one
of
the
most
pressing
global
health
challenges
and
a
leading
cause
death-through
development
liposomes
(L),
lipid-based
nanovesicles
known
for
their
biocompatibility
ability
to
encapsulate
both
hydrophilic
lipophilic
drugs.
More
recent
innovations
led
creation
stimuli-responsive
L
that
release
payloads
response
specific
endogenous
or
exogenous
triggers.
Dual-
multi-responsive
L,
which
react
multiple
stimuli,
offer
even
greater
precision,
improving
therapeutic
outcomes
while
reducing
systemic
toxicity.
Additionally,
these
smart
can
adjust
physicochemical
properties
morphology
enable
site-specific
targeting
controlled
drug
release,
enhancing
treatment
efficacy
minimizing
adverse
effects.
This
review
explores
latest
liposomal
nanocarriers,
as
well
dual-
integrate
internal
external
triggers,
with
focus
on
design
strategies,
mechanisms,
applications
therapy.
Applied Biosciences,
Journal Year:
2025,
Volume and Issue:
4(1), P. 16 - 16
Published: March 5, 2025
Hematologic
malignancies,
including
leukemia,
lymphoma,
and
multiple
myeloma,
pose
significant
therapeutic
challenges
due
to
their
heterogeneity
high
relapse
rates.
Nanotechnology
has
emerged
as
a
promising
avenue
for
precision
drug
delivery
in
these
allowing
enhanced
concentration
at
tumor
sites
reducing
systemic
toxicity.
Recent
developments
nanocarriers—such
liposomes,
polymeric
nanoparticles,
inorganic
nanoparticles—have
enabled
targeted
approaches,
utilizing
molecular
markers
specific
malignant
cells
increase
efficacy
while
minimizing
adverse
effects.
Evidence
from
preclinical
clinical
studies
underscores
the
potential
of
nanotechnology
improve
patient
outcomes
by
facilitating
controlled
release,
improved
bioavailability,
reduced
However,
translating
advancements
into
practice
requires
further
research
validate
safety
efficacy.
This
review
provides
comprehensive
analysis
latest
innovations
hematologic
addressing
current
achievements
future
directions
integrating
approaches
Clinical
Hemato-Oncology.
